Chemistry:Sivifene
 | |
| Clinical data | |
|---|---|
| Other names | A-007; 4,4'-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone |
| Routes of administration | Topical |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C19H14N4O6 |
| Molar mass | 394.343 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Sivifene (INN, USAN; developmental code name A-007) is a small-molecule antineoplastic agent and immunomodulator that was under development in the 2000s by Tigris Pharmaceuticals (now Kirax Corporation) as a topical treatment for cutaneous cancer metastases.[1][2][3] It was specifically being investigated to treat high-grade squamous intraepithelial lesions (HSIL) associated with human papillomavirus (HPV) infection and invasive carcinomas of the anogenital area such as cervical, vaginal, and anal cancers.[1] The drug reached phase II clinical trials prior to its discontinuation.[1]
Initially, due to its structural similarity to tamoxifen, sivifene was thought to be a selective estrogen receptor modulator (SERM), but subsequent research revealed that it does not bind to the estrogen receptor (ER) and does not possess antiestrogenic activity.[2] The actual mechanism of action of sivifene is unknown, but it is thought to produce its immunomodulating effects via upregulation of the CD45 T-lymphocyte cell surface receptor.[2]
See also
References
- ↑ 1.0 1.1 1.2 "Sivifene - AdisInsight". http://adisinsight.springer.com/drugs/800002477.
- ↑ 2.0 2.1 2.2 "4,4'-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007): a topical treatment for cutaneous metastases from malignant cancers". Cancer Chemother. Pharmacol. 57 (6): 719–26. 2006. doi:10.1007/s00280-005-0124-2. PMID 16184382.
- ↑ Robert A. Schwartz (30 April 2008). Skin Cancer: Recognition and Management. John Wiley & Sons. pp. 267–. ISBN 978-0-470-69563-0. https://books.google.com/books?id=kOK1J0Xzg0gC&pg=PA267.
External links
 |  |
